BNT162b2 and ChAdOx1 nCoV-19 Vaccine Effectiveness against Death from the Delta Variant
- 2 December 2021
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (23), 2195-2197
- https://doi.org/10.1056/nejmc2113864
Abstract
We recently reported vaccine effectiveness for the BNT162b2 vaccine (Pfizer–BioNTech) and the ChAdOx1 nCoV-19 vaccine (AstraZeneca) against infection and hospitalization caused by the B.1.617.2 (delta) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Scotland.1 At that time, the number of deaths was too small to allow estimation of vaccine effectiveness against death from infection with the delta variant.Keywords
Funding Information
- Medical Research Council (MR/R008345/1)
This publication has 5 references indexed in Scilit:
- SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectivenessThe Lancet, 2021
- Cohort Profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) DatabaseInternational Journal of Epidemiology, 2021
- Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort studyThe Lancet, 2021
- Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort studyBMJ, 2020
- Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national dataBMJ Open, 2020